Solid Biosciences Inc. (SLDB) stock
SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.23−0.25 (-3.86%)
Close on Nov 17, 2026Market cap $668.01MP/E –Yield –
Earnings
Solid Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2022
$6.20M
EPS, Q2 FY2022
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Solid Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Mar 6, 2026after the close | – | – | – | Filing |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 18, 2025before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 8, 2024before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Jan 9, 2023before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022before the open | $6.20M | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 27, 2022before the open | $1.90M | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Jan 10, 2022before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 16, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 14, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 15, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 23, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 12, 2020before the open | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 14, 2019before the open | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 13, 2019after the close | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Mar 13, 2019before the open | – | – | – | Filing |
| Q3 FY2018ended Sep 30, 2018 | Nov 13, 2018before the open | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 10, 2018before the open | – | – | – | Filing |
| Q1 FY2018ended Mar 31, 2018 | May 10, 2018before the open | – | – | – | Filing |
| Q4 FY2017ended Dec 31, 2017 | Mar 29, 2018before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Solid Biosciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Solid Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Solid Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Update
- Update
- News
- News
See a number that looks wrong?